Angiotensin Converting Enzime Receptor and COVID-19 Correlation ¿What do we know so far?
PDF (Español)


Angiotensin Receptors, COVID-19, severe acute respiratory syndrome, SARS-CoV-2, coronavirus infection (MeSH).

How to Cite

Pulido Saenz JA, Trujillo J, Díaz L, Barba N. Angiotensin Converting Enzime Receptor and COVID-19 Correlation ¿What do we know so far?. Rev. Colomb. Nefrol. [Internet]. 2020 Jun. 3 [cited 2024 Jul. 16];7(Supl.2). Available from:


Introduction: As a new disease, SARS-COV-2 is a new challenge for healthcare system worldwide, with physiopathology under study and controversy about Angiotensin Converting Enzyme Blockers use because of It’s physiopatological correlation with SARS-Cov-2.

Objetive: Search for novel literature and recent recomendations about use of Angiotensin Converting Enzyme Blockers during Covid-19 illness.

Materials and Methods: We look for narrative literature at PubMed Database for articules about Angiotensin Converting Enzyme and Covid-19 pandemic. Searching limit wasApril 13 of 2.020, we included all languages.

Results: We included 14 articles with significative scientific contentfor review objetive.   

Conclusion: SARS-Cov-2 Physiopatology is still unclear, also, pharmacology effectiveness in it’s treatment. One of these pharmacology groups are the Angiotensin Converting Enzyme Blockers with uncertainty about it’s safety during COVID-19 illness.
PDF (Español)


Sun P, Lu X, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020;92(6):548-51

Li Q, Guan X, Wu P, Wnag X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020;382(13):1199-1207.

Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The emerging impasse of Angiotensin Blockade. Nephron. 2020;144:213-21.

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20.

World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19): Situation Report - 68 (28 March2020). Geneva: WHO; 2020.

Colombia. Instituto Nacional de Salud (INS). COVID-19 Colombia. Reporte 18/03/2020. Bogotá D.C.: INS; 2020.

Colombia. Ministerio de Salud Colombia (MinSalud). Análisis de Situación de Salud (ASIS). Bogotá D.C.: MinSalud; 2017.

Moya L, Moreno J, Lombo M, Guerrero C, Aristizábal D, Vera A, et al. Consenso de Expertos sobre el manejo clínico de la hipertensión arterial en Colombia. Sociedad Colombiana de Cardiología y Cirugía. Rev Colomb Cardiol. 2018;25(Suppl 3):4-26.

Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19, N Engl J Med. 2020;382(17):1653-9.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.e8.

Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res. 2020.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor- binding domain (RBD) of the novel coronavirus: Implication for the development of RBD Protein as a viral attachment inhibitor and vaccine. Cell Mo Immunol. 2020;17(6):613-20.

Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus - Induced lung ingury, Nat Med. 2005;11(8):875-9.

Fedson DS, Opal SM, Rordam OM. 2020. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. mBio 2020;11(2):e00398-20.

No national or foreign publication may partially or totally reproduce or translate Revista Colombiana de Nefrología articles or abstracts without prior written permission from the journal’s Editorial Board.




Download data is not yet available.